Initially synthesised at the Hebrew University by a Professor Raphael Mechoulam, HU-210 is a potent full agonist for the CB1and CB2cannabinoid receptors which induces psycoactive effects which are similar to but signifiganlty stronger than natural THC. HU-210 has a higher binding affinity for the CB1receptor over the CB2receptor, binding to the CB1receptors with almost the same affinity as CP 55,940.Aside from its psychoactiveeffects, HU-210 has been shown to prevent inflammation caused by amyloid beta proteins which are involved in the development of Alzheimer's disease, on top of that HU-210 has been shown to prevent cognitive impairment and loss of neuronal markers. The anti-inflammatory action caused by HU-210 is induced through the activation of the CB1and CB2cannabinoid receptors, preventing microglial activation which is the cause of inflammation. In addition to these protective effects, HU-210 also has been shown to abolish neurotoxicity related to microglial activation in rats.